Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer.

Oncol Lett 2017 Aug 16;14(2):2334-2340. Epub 2017 Jun 16.

Department of Obstetrics and Gynecology, Medical Center - University of Freiburg, D-79106 Freiburg, Germany.

Tumor resistance to endocrine therapy triggers estrogen-independent cancer progression, which is a major obstacle to the successful treatment of hormone receptor positive breast cancer (BC). The underlying molecular mechanisms of endocrine resistance are not fully understood yet. The matricellular protein cysteine-rich angiogenic inducer 61 (Cyr61) is associated with tumor invasiveness and the induction of tumorigenesis in various malignancies and the induction of estrogen-independence and endocrine therapy resistance in BC. The present study evaluated the potential effects and clinical relevance of Cyr61 expression levels in 67 patients with primary non-metastatic BC. Immunohistochemical analysis of formalin-fixed paraffin-embedded tissue sections was performed, and the association between Cyr61 protein expression and clinicopathological factors and survival was analyzed. Cyr61 overexpression was revealed to be significantly associated with a positive estrogen receptor (ER)/progesterone receptor (PR) status (P=0.016) and to the molecular subtype of BC (P=0.039). Compared with patients without Cyr61 overexpression, patients with Cyr61 overexpression exhibited an increased recurrence rate (30.6 vs. 22.6%) and decreased long-term survival (10-year overall survival, 62.9 vs. 69.7%); however, these associations did not reach statistically significant levels in Cox regression model analysis. Similar results were identified in the subgroup analysis of patients with ER/PR positive BC. These results indicate that Cyr61 serves a role in the development of endocrine therapy resistance in BC and is thus a potential therapeutic target to overcome endocrine therapy resistance. However, additional long-term survival analyses with large patient populations are required.

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2017.6406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529991PMC
August 2017
51 Reads

Publication Analysis

Top Keywords

endocrine therapy
16
therapy resistance
12
cyr61 overexpression
12
breast cancer
8
patients cyr61
8
long-term survival
8
relevance cyr61
8
clinical relevance
8
cyr61 expression
8
cyr61
8
resistance
5
endocrine
5
patients
5
revealed associated
4
receptor status
4
status p=0016
4
er/progesterone receptor
4
associated positive
4
estrogen receptor
4
receptor er/progesterone
4

Similar Publications